Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week High at $32.37

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Rating) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $32.37 and last traded at $32.37, with a volume of 8780 shares changing hands. The stock had previously closed at $29.10.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GPCR. SVB Leerink reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 28th. Jefferies Financial Group assumed coverage on shares of Structure Therapeutics in a research note on Thursday. They set a “buy” rating and a $41.00 price target on the stock. BMO Capital Markets assumed coverage on shares of Structure Therapeutics in a research note on Tuesday, February 28th. They set an “outperform” rating and a $40.00 price target on the stock. Guggenheim assumed coverage on shares of Structure Therapeutics in a research note on Tuesday, February 28th. They set a “buy” rating and a $50.00 price target on the stock. Finally, SVB Securities assumed coverage on shares of Structure Therapeutics in a research note on Tuesday, February 28th. They set an “outperform” rating and a $33.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $41.00.

Structure Therapeutics Trading Up 14.6 %

The business’s 50 day moving average price is $24.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC purchased a new position in Structure Therapeutics in the first quarter valued at approximately $29,724,000. Price T Rowe Associates Inc. MD purchased a new position in Structure Therapeutics in the first quarter valued at approximately $18,711,000. BlackRock Inc. purchased a new position in Structure Therapeutics in the first quarter valued at approximately $9,516,000. Franklin Resources Inc. purchased a new position in Structure Therapeutics in the first quarter valued at approximately $7,732,000. Finally, Wellington Management Group LLP purchased a new position in Structure Therapeutics in the first quarter valued at approximately $2,377,000.

Structure Therapeutics Company Profile

(Get Rating)

Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc is based in SAN FRANCISCO.